Provided by Tiger Trade Technology Pte. Ltd.

Nexien BioPharma, Inc.

0.0001
0.0000
Volume:1.00
Turnover:0.00
Market Cap:7.08K
PE:-0.04
High:0.0001
Open:0.0001
Low:0.0001
Close:0.0001
52wk High:0.0145
52wk Low:0.0001
Shares:70.77M
Float Shares:26.27M
Volume Ratio:0.00
T/O Rate:0.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0028
EPS(LYR):-0.0036
ROE:-4070.45%
ROA:-655.83%
PB:-0.02
PE(LYR):-0.03

Loading ...

May 14, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Feb 14, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 18, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Oct 22, 2024

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
May 15, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Feb 20, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 15, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Sep 28, 2023

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
May 17, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Feb 08, 2023

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 09, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Sep 28, 2022

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
May 12, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Feb 08, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Jan 21, 2022

Major Issues Report

8-K - Current report
Nov 22, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Oct 12, 2021

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
May 05, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Feb 11, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 10, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]